Clinical Trial Update: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 trial assessing atezolizumab/bevacizumab followed by on-demand TACE or initial synchronous TACE with atezolizumab/bevacizumab for unresectable hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: RECRUITING